If you are an athlete or a bodybuilder looking for ways to decrease body fat whilst increasing muscle mass then GHRP 2 and GHRP 6 (the two types of Growth Hormone Releasing Peptides) can certainly help you with your requirements. The best part with these hormones is that you are likely to get the desired results out of them, especially when you combine them with muscle building and fat-burning foods, aerobic and intense strengthening exercises. However, there are subtle differences between the two hormones that you cannot ignore. 

Determining how efficient and the actions of the growth hormone is dependent on the physical condition of the experimental unit. For example, in humans, GH secretion decreases with obesity. On the other hand, GHRP-6, similar to Hexarelin, showed in one case increased (almost twice that of GHRP) GH responses when administered in obese patients (Cordido et al. 1993). Though obesity has shown affecting the efficiency of the hormone, it was also suggested that GHRP-6’s effects were found to be sex- and age-independent without being affected by the noadregenic pathways using the a2 adrenergic receptors (Penalva et al. 2008).
Peptidyl and nonpeptidyl GHSs are active when administered by intranasal and oral routes, are more potent on a weight basis than GHRH itself, are more effective in vivo than in vitro, synergize with coadministered GHRH and are almost ineffective in the absence of GHRH, and do not suppress somatostatin secretion. Prolonged infusions of GHRP amplify pulsatile GH secretion in normal men. GHRP administration, like that of GHRH, facilitates slow-wave sleep. Patients with hypothalamic disease leading to GHRH deficiency have low or no response to hexarelin; similarly, pediatric patients with complete absence of the pituitary stalk have no GH secretory response to hexarelin.
As with any GHRP or GHRH, administration of GHRP-6 doses should be done no sooner than 2 hours following the last meal containing carbohydrates or fats, and no sooner than 30 minutes prior to the next consumption of carbohydrates or fats. As evidenced by studies referenced in the introduction of this profile, the consumption of fats and carbohydrates will significantly blunt (but not eliminate) HGH release. HGH pulses will generally reach their peak by about 30 minutes following injection, after which it is then acceptable to consume a meal containing carbohydrates and fats.
Scheduling both enobosarm and SARMs would address the potential problem of misuse and abuse. The class entry for SARMs was recommended as there are other SARMs being developed. Patients being treated with these drugs would require medical diagnosis, monitoring and management. There is access to SARMs that are more toxic than enobosarm. If only one SARM was scheduled, consumers would be able to source another SARM.
If you’re looking to increase your muscle growth and improve strength, whether for competitive bodybuilding or to achieve a personal physique goal, our Australian muscle building peptide supplements can help. Our dedicated research and product development team have consistently produced new products that perform better than other supplement brands, so you know you’ll be getting the best peptide supplements available. If you’re new to peptide supplements and have questions, read our FAQ’s, or alternatively email us at info@musclepeptidesaustralia.com.au and our clinic doctor can help you with your questions.
If you’re looking to increase your muscle growth and improve strength, whether for competitive bodybuilding or to achieve a personal physique goal, our Australian muscle building peptide supplements can help. Our dedicated research and product development team have consistently produced new products that perform better than other supplement brands, so you know you’ll be getting the best peptide supplements available. If you’re new to peptide supplements and have questions, read our FAQ’s, or alternatively email us at info@musclepeptidesaustralia.com.au and our clinic doctor can help you with your questions.
The use of peptides is not necessarily a case of one or the other. While you can derive benefit from using either GHRH or GHRP, the effects can be amplified by using both. This, for one, will help to better keep levels of somatostatin under control. The amount of that hormone is an issue you will be forced to contend with when using only GHRH. This is because it is known to inhibit growth hormone.
Figure 6: Microscopic aspect of the rabbits’ ears wounds. (a) Representative image of “nipple” in which, above the cartilage and the perichondrium, there is a prominent accumulation of extracellular matrix. (b) Representative image of the effect induced by the GHRP-6 intervention. Note the reduction of extracellular matrix accumulation within the injured area. The “flattening” aspect is indicated by the solid line arrow. The dotted arrows indicate that the elevation within the center of the scar is similar to the adjacent intact skin. Images suggest that GHRP-6 reduced the local hypercellularity associated with the cartilage cells response. H/E 10x magnification.
IGF-1 causes hyperplasia and muscle and strength increase, looove IGF-1 (insulin-like growth factor). GHRP-6 causes your pituitary gland the secret growth hormones so you get a 'pulse' after each shot. The more shots, the more pulses you get which is why I split it up to 3 times a day. You feel amazing post-shot and also hungry as fuuu within 20 minutes, like a bottomless stomach. Also helps with fat-loss.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
The mechanisms supporting the GHRP-6-mediated HTS prevention may be related to a potential modulation of the fibrogenic response, especially by TGF-β1 transcriptional deactivation and its downstream effector CTGF, as has been previously described [30]. Nevertheless, we have not elucidated the pathways involved in the GHRP-6-mediated TGFB1 gene expression reduction. Under these circumstances, we have reproducibly observed [7] that GHRP-6 increases PPARG expression which may have counteracted TGF-β1-associated fibrogenic input. The fact that CD36 occupation by GHRP-6 upregulates PPARG gene expression is noteworthy in this context and represents an additional pharmacologic property for this peptide. Although the molecular pathways underlying the antifibrotic effects of PPARγ remain elusive, an antagonistic relationship is proposed between PPARγ and TGF-β1 signaling in fibrosis. For more than a decade ago, PPARγ has been reputed as a fibrosis-response regulating factor and its activation represents an innovative pathway to control fibrotic diseases [31, 32].
The most important initial historical time points in the development of the enlarging ghrelin system were 1973, 1976, 1982, 1984, 1990, 1996, 1998, and 1999 during which the following sequentially occurred: isolation of somatostatin; discovery of unnatural growth-hormone-releasing peptides (GHRPs); isolation of growth-hormone-releasing hormone (GHRH); hypothesis of a new natural GHRP different from GHRH; GHRP+GHRH synergism in humans; discovery of the growth hormone secretagogue GHS/GHRP receptor; cloning of the receptor; isolation; and identification of the new natural endogenous GHRP ghrelin.1

The Half Life of GHRP 2 is pretty short. GHRP 2 helps improve the levels of calcium in the body and this can in turn facilitate the secretion of other growth hormones. GHRP 2 is believed to be more potent in its operation as compared to other peptide forms, including GHRP 6. GHRP 2 has the ability to stimulate secretion of other growth hormones and increase food consumption. When you start taking in GHRP 2 at regular intervals the level of growth hormones being released in your body increases considerably. GHRP 2 is known to have better control in the release of prolactin and Cortisol. 
At the time that decision was made, paracetamol/caffeine combinations were available over-the-counter in over 50 other countries and had been exempt from scheduling in a number of major markets that are similar to Australia in terms of population type and regulatory status. Experience with the unscheduled sale of this product was extensive: UK 19 years, Ireland 12 years and New Zealand for 7 years. However, the Committee determined not to consider paracetamol combined with caffeine for exemption from scheduling until market experience had been gained with use as a Schedule 2 product in Australia.
GHRP was first envisioned to be an analog of GHRH but, from comparison of the activity of GHRH and GHRPs between 1982 and1984, it was hypothesized to reflect the activity of a new hormone regulator of GH secretion, yet to be isolated and identified. Intravenous bolus GHRP releases more GH than GHRH in humans, but the reverse occurs in vitro. GHRPs are pleiotropic peptides with major effects on GH, nutrition, and metabolism, especially as an additional hormone in combination with GHRH as a new regulator of pulsatile GH secretion. The first indication of pleiotropism was an increase of food intake by GHRP. A major reason for the prolonged initial interest in the GHRPs has been its similar, yet different and complementary, action with GHRH on GH regulation and secretion.

So… now we get down to the individual peptides themselves. I will not go into length with a profile for each one, but instead I will provide two charts that should help in understanding which peptides are GHRH’s and which ones are GHRP’s. Of course, IGF and MGF have their own respective spots but do not have the synergy when combined like GHRP and GHRH.
Hexarelin via CD36 occupation increases the expression of multiple genes involved in fatty acid mobilization in adipocytes toward the mitochondrial oxidative phosphorylation, and many of these upregulated genes are known targets of PPARγ. Consistent with this, electron microscopy of hexarelin-treated adipocytes reflects highly organized cristae formation that spans the entire width of mitochondria, with a concomitant cytochrome c oxidase activity enhancement. Although this signaling and activation cascade has not been described for myocardial cells so far, the potential existence of these phosphorylative and mitochondriogenic mechanisms in the heart, and its potential amplification by GHRP ligands, may eventually contribute to myocardial salvage during critical ischemia periods.47 In a more recent study based on a myocardial infarction model, and addressed to examine whether hexarelin treatment can compensate for ghrelin deficiency in ghrelin-knockout mice, the mortality within two weeks was significantly lower in the hexarelin (6.7%) and ghrelin groups (14.3%) than in the vehicle group (50%). Furthermore, hexarelin was more effective than ghrelin as judged by the ejection fraction and other LV-dependent physiological constants as dP/dt max and dP/dt min, which is a measure of LV global contractility.48
In another study, it was concluded that the major target of the GHRP-6 in vivo (both laboratory animals and humans) is the hypothalamus. From the observation, it was concluded that the GH release induced by the central GHRP-6 injections in guinea pigs was inhibited by the central action of somatostatin. Furthermore, an inhibition by somatostatin with the activated GRF neurons, induced by GHRP-6, was observed via receptors known to be located on or near the GRF themselves. This particular experiment further indicated that GHRP-6 is effectively stimulating GH release from somatotrophs through different receptors, the mechanisms of which are not yet known (Chan et al. 1989).

Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.
As judged by the PubMed outcomes, the cytoprotective effects of synthetic peptidyl GHRP appear far less studied in noncardiac, parenchymal epithelial organs or multiple organ systems than in the cardiovascular system. However, the results of the reviewed studies are consistent with a broad cytoprotective influence for various organs by reducing inflammation and preventing necrosis and/or apoptosis. The mechanism of GHRP-mediated pharmacological actions is shown in Figure 4.
Mostly, these peptides are sold as lyophilized powder in 2mg containers. Bacteriostatic water should be mixed with the powder in order to reconstitute it. To make the dosage of 100mcg per injection, 2ml bacteriostatic water should be mixed into 2mg of lyophilized powder. This reconstituted mixture should be then injected inside the muscles or under the skin. The mixture should be kept under refrigeration at all times otherwise it will degenerate and will not be effective anymore.
This duration is a sufficient time to allow the ghrelin peptide to work through your system, and also for it to have a long lasting effect with continued use. It will work to enhance the hormone system, increase the metabolic rate, and increase lean muscle tissue levels in this period of time. As discussed above, the proper dosage for new users is 200 to 300 mcg daily, at the same time each day. For more experienced users, you can take the same dosage, 2 to 3 times a day (remember that it is the same time each day, and is best to use your injection after a meal for the best results possible).
Yes, Ipamorelin can help you lose weight. But, if you are not exercising, and aren’t eating well, it can only do so much. There is no magical supplement which will undo laziness and a horrible diet – keep this in mind. When using it for fat loss, make sure you are exercising. Doing so will naturally increase weight loss results, as you are going to burn more calories, along with the caloric deficit you are already on, for greater results. Further, your diet matters. If you are eating 5000 calories of junk per day, no supplement will help you lose weight – no matter how potent it claims to be!
The ACMS recommended that Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604 be included in Schedule 4.

Ghrelin has been linked to inducing appetite and feeding behaviors. Circulating ghrelin levels are the highest right before a meal and the lowest right after. Injections of ghrelin in both humans and rats have been shown to increase food intake in a dose dependent manner. So the more ghrelin that is injected the more food that is consumed. However, ghrelin does not increase meal size, only meal number. Ghrelin injections also increase an animals’ motivation to seek out food, behaviors including increased sniffing, foraging for food, and hoarding food. Ghrelin also readies the body for the incoming nutrients by stimulating gastrointestinal motility and gastric acid secretions.

In April and November 1994 and May 1995, the NDPSC decided to amend the scheduling of hydrogen peroxide to include exemptions for hair preparations: 6 per cent or less in the Schedule 5 entry because of the packaging and low exposure potential and 12 per cent or less in the Schedule 6 entry to capture hair dye preparations containing >6 per cent up to 12 per cent in Schedule 5. The NDPSC also decided that the hydrogen peroxide concentration would determine the appropriate warning statements.
In June 2005, the NDPSC decided to reschedule pantoprazole from Schedule 4 to Schedule 3 when in oral preparations containing 20 mg or less of pantoprazole for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease (GORD), in packs containing not more than 14 days' supply. This decision was based on the available efficacy and safety data which supported a Schedule 3 entry.
CJC 1295 is a fast working growth hormone releasing hormones devised to reduce the effects of ageing. It works by stimulating the body’s natural growth hormone production and the release of IGF-1. The advantages of the CJC peptide is it helps increases bone density and collagen, as well as boosting the immune system. It will also produce new muscle cells which will be leaner and increases weight loss. The CJC 1295 results are part of years of scientific studies. It primarily increases the production of proteins, which leads to stable bodily functions related to the glands in the body or the endocrine system.
Our group recently demonstrated the antifibrotic effects of the growth hormone-releasing peptide 6 (GHRP-6) in a rat model of liver cirrhosis. GHRP-6 prevented parenchymal fibrotic induration in more than 85% and removed in about 75% the accumulated fibrotic material in both preventive and therapeutic administration schemes. Differentially expressed genes in a microarray experiment indicated that GHRP-6 modulates the expression of genes involved in the redox metabolism, as in the mesenchymal cells response to injury [7].
Ipamorelin is a pentapeptide, meaning that it is composed of five amino acids, that mimics the body’s natural GH release.  Ipamorelin is a growth hormone releasing peptide (GHRP) and analogue of the hormone Ghrelin. It induces GH release and increases the number of somatarophs(cells responsible for GH release) in a GH pulse by suppressing somatostatin.

Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.


Similar to GHRP 2, this peptide is a more potent releaser of growth hormone, also acting on the ghrelin receptors of the anterior pituitary. Also like GHRP 2, GHRP 6 leads to increased growth hormone production, increased lead body mass, and decreased adiposity. Due to the peptide’s ghrelin-like properties, administration can lead to increased appetite.

Great, I just filled a script for ipamorelin yesterday and it will ship today. This will be the 1st time use. I’m 41, 6’1 210 pretty fit, recently had an acl replaced 1.5 yr ago and a wrist surgery, and have some lower back and shoulder pain that I ignore. How long/short could I use this to feel any rebuilding effect. I certainly don’t want bloat, or cancer. I might be able to cancel the order 1st thing this a.m. Thanks.
Finally, the ghrelin chemical isolation and identification was accomplished surprisingly from the stomach, which is the major site but not the only site. Ghrelin was isolated and identified.4 A primary action of GHRPs continues to concern GH secretion and regulation, but increasingly this has included direct and indirect effects on nutrition and metabolism, as well as a variety of other actions which may be pharmacological and/or physiological.
Three of the submissions did not support the proposal highlighting the impact the change in scheduling would have on product currently on the market, industry, pharmacists and consumers. Two submissions noted that there has not been a history of concern with this combination of substances. One submission, referring to the NEJM article, believed that a lack of information about the study means that it cannot be relied upon as there is not a meaningful assessment of the results.
The letters stand for ‘Growth Hormone Releasing Peptide’, and the compound is a peptide in the growth factor family, known as a HEXAPEPTIDE and GH SECRATAGOGUE. It has a strong effect on the release of endogenous (naturally produced) human growth hormone, in a dose related manner. It has been used in school medicine for the treatment of growth hormone deficiency in children and young adults, which drives home just how powerful this compound is at influencing the body to release its own natural GH. It works by signalling the pituitary gland to secrete GH itself, but also by the suppression of SOMATOSTATIN too (an antagonist of growth hormone releasing hormone – GHRH).

Excerpt: I started taking Ipamorelin and CJC 1295 without DAC yesterday. I dont see many logs and i see a lot of people wondering what kind of results you can get wiith these peptides. I have enough to go a couple of months right now and see what this stuff is really about. Im taking each 3x a day. Morning, pwo, and before bed. Im taking 100mcgs of each in the morning and before bed. After my workout, I'll take 100mcgs of cjc and 100-200mcgs of Ipa. I weigh 215 and i have no idea what my bodyfat
Thymosin alpha-1 (T α 1) is a peptide, or small protein, consisting of 28 amino acids. T α 1 is produced naturally by the thymus gland. The thymus is located behind the sternum and between the lungs, and is where immune cells known as T cells mature and are released, prompted to do so by the T α 1 peptide. T cell production and action within the body is vital to adaptive immunity—the mode by which immune cells are able to recognize and eradicate foreign invaders.
Growth Hormone Releasing Peptide-6 is responsible for releasing growth hormone in appropriate quantities in the body and it does so by stimulating the pituitary gland. So what are the benefits of this hormone secretion process? Your body composition is likely to improve substantially once the GHRP 6 starts doing its work of secreting growth hormone. As a result of all this, individuals who are striving hard to get the body they are after will achieve their objective in a quick time and will also feel a lot better on the whole.
×